On February 18, 2021, New Horizon Health Limited issued 76,598,000 shares worldwide (excluding over-allotment) and listed on the Main Board of the Stock Exchange of Hong Kong at a price of HK $26.66 per share, raising more than HKD $2 billion. New Horizon Health Limited is the first listed company in the field of early cancer screening in China. JunHe acted the PRC legal counsel of the co-sponsors Goldman Sachs and UBS Securities Co., Ltd.
New Horizon Health Limited was founded in 2015 and is a pioneer in China's early cancer screening and home testing business. Through screening and early detection, New Horizon aims to ultimately achieve cancer prevention and cure. New Horizon Health Limited 's core product, Chang Weiqing, is China's first and only FDA -approved molecular cancer screening test. Chang Weiqing is a non-invasive home early screening test for colorectal cancer and uses a multi-targeted FIT-DNA assay. The product was designed for the Chinese population and is recommended by many national authoritative clinicians. It aims to test China's 120 million citizens who are most at risk of colorectal cancer. In addition, the company has a number of pipeline products suitable for gastric and cervical cancer screening.
JunHe acted as the co-sponsors and underwriter’s PRC legal counsel of this Project and provided high quality, rigorous and efficient legal services. JunHe’s team overcame the many adverse effects of the epidemic, and assisted the co-sponsor in carrying out due diligence. The team reviewed and amended the prospectus, the application and the offering documents related to this listing. They issued PRC legal opinions, assisted in replying to feedback questions from the Hong Kong Stock Exchange about PRC law and ultimately assisted New Horizon Health Limited to successfully obtain approval and consent for the listing application from the Hong Kong Stock Exchange. JunHe 's solid work attitude and professional service won unanimous recognition and high trust from their clients and other intermediaries.